Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced the extension of their oncology collaboration for first in human clinical trials for drug candidates LP-184 and LP-284.
Drug and target discovery company Absci has signed a research collaboration with Merck to produce new enzymes.
Amgen has entered into a research collaboration agreement with Generate Biomedicines to discover and create protein therapeutics for five clinical targets across several modalities.
Ovid Therapeutics has signed a license agreement with AstraZeneca for a library of early-stage small molecules that target the KCC2 transporter.
Ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Under the deal, AstraZeneca will manage the development and marketing of the antisense therapy globally.
BSF Enterprise has signed a conditional agreement to acquire 3D Bio-Tissues (3DBT) in a deal worth $3.34m (£2.5m).
Ambys Medicines has secured $47m Series A financing extension for the continued expansion of its production capabilities of liver cell therapy.
Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases.
Bristol Myers Squibb has signed a license, development, and commercialisation agreement with clinical-stage biopharmaceutical firm Immatics for the latter's TCR Bispecific candidate for solid tumours, IMA401.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.